SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q1 Trading Update

19 Apr 2018 07:00

RNS Number : 3888L
Rentokil Initial PLC
19 April 2018
 

 

RENTOKIL INITIAL PLC (RTO)

FIRST QUARTER TRADING UPDATE

19 April 2018

 

(£m)

 

Q1 2018

Growth

 

 

AER

AER

CER

Ongoing Revenue1

 

545.9

10.8%

15.7%

Revenue

 

550.7

-5.1%

-1.5%

 

Overview

Trading has started well across our businesses in Q1 with Ongoing Revenue increasing by 15.7%.

Organic Revenue2 Growth of 3.2% compares to Q1 2017 at 3.7%* (3.1% Reported) and Q4 2017 (3.1%). Organic growth has been affected by the ongoing impact of last September's hurricane on our operations in Puerto Rico (as previously highlighted at the time of our Preliminary results) and unseasonably cold weather in the US in March which has delayed the onset of the spring pest season. Excluding the impact of Puerto Rico, 2018 Q1 Organic growth is in line with Q1 2017.

Acquisitions have performed well contributing 12.5% to Ongoing Revenue in the first quarter.

Ongoing Revenue in Pest Control grew by 15.8% (4.7% Organic, Q1 2017: 5.6%, Q4 2017: 4.9%) with Growth markets growing by 12.4% and Emerging markets increasing by 38.2%, reflecting the strong performance of our joint venture in India.

Q1 2018 Hygiene Ongoing Revenue rose by 29.3% (1.8% Organic, Q1 2017: 3.4%, Q4 2017: -0.2%), driven by the acquisitions of Cannon Hygiene and CWS Italy.

Ongoing Revenue in our Protect & Enhance markets declined by -0.1% (-0.3 Organic, Q1 2017: -0.9%, Q4 2017: 1.0%) due to ongoing market weakness in our UK Property Care business, offset by a stronger performance from our French business.

While currency markets remain volatile, our guidance for the adverse impact of foreign exchange on profit is in the range of £10m to £15m for the year, as previously guided at the Preliminary results on 1 March 2018.

M&A 

​In the three months to 31 March 2018 we made 11 pest control acquisitions (five in North America with annualised revenues of $27m) in addition to the Cannon Hygiene businesses acquired in January. Combined annualised revenues of the 12 businesses acquired was £103.0m in the year prior to purchase. Our guidance for M&A spend remains in the range of £200m to £250m which will be funded by cash held on the balance sheet at the beginning of the year. We are encouraged about our prospects for further M&A this year and our pipeline of value-enhancing opportunities is strong.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am pleased with our performance in Q1 and we are well-positioned for another year of successful growth. We are confident that the Company will deliver a performance in line with market expectations for 2018."

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

 

 

 

 

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

 

 

 

 

 

 

 

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

*In Q1 2017 the Company reported Organic growth of 3.1% in Q1 but noted that excluding the businesses transferred to the Haniel JV, the Organic growth figure would have been 3.5%. We have further adjusted this number to exclude the eight French flat linen laundries sold to RLD in H2 2017, which results in a revised comparative number for Q1 2017 of 3.7%.

 

AER - actual exchange rates; CER - constant 2017 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTMMGMDNRFGRZM
Date   Source Headline
31st Mar 20211:16 pmRNSTotal Voting Rights
31st Mar 202110:33 amRNSAnnual Financial Report
30th Mar 20216:23 pmRNSDirector Declaration
24th Mar 20215:55 pmRNSDirector/PDMR Shareholding
12th Mar 20219:00 amRNSAdditional Listing
4th Mar 20217:05 amRNSDirectorate Change
4th Mar 20217:00 amRNSFinal Results
17th Feb 20215:45 pmRNSDirector Declaration
8th Jan 20217:00 amRNSQ4 2020 Acquisitions and Trading Update
27th Nov 20202:25 pmBUSEarly Repurchase(s)
27th Nov 20202:22 pmBUSEarly Repurchase(s)
24th Nov 20205:25 pmRNSDirector/PDMR Shareholding
20th Nov 20207:00 amRNSResult of Tender Offer for Notes due 2021
12th Nov 20209:02 amRNSTender Offer for Notes due 2021
22nd Oct 20207:00 amRNSQ3 Trading Update
8th Oct 20207:00 amRNSSuccessful EUR600m 8-year bond transaction priced
1st Oct 20209:00 amRNSBlock listing Interim Review
28th Aug 20203:40 pmRNSDirector/PDMR Shareholding
7th Aug 20205:24 pmRNSDirector/PDMR Shareholding
30th Jul 20207:00 amRNSInterim Results
6th Jul 20207:00 amRNSDirectorate Change
21st May 202011:00 amRNSDirector/PDMR Shareholding
13th May 20205:15 pmRNSResult of AGM
7th May 20204:45 pmRNSDirector/PDMR Shareholding
27th Apr 20203:50 pmRNSDisclosure of Rights Attached to Equity Shares
17th Apr 202011:59 amRNSDirector/PDMR Shareholding
16th Apr 20207:00 amRNSQ1 Trading Update
14th Apr 20205:26 pmRNSHolding(s) in Company
9th Apr 20204:35 pmRNSDirector/PDMR Shareholding
2nd Apr 20201:36 pmRNSDirector/PDMR Shareholding
1st Apr 20205:33 pmRNSConfirmation of Non-Executive Director Appointment
1st Apr 20209:24 amRNSBlock listing Interim Review
31st Mar 20202:18 pmRNSTotal Voting Rights
30th Mar 202012:37 pmRNSRedemption of 4.5% debenture stock
30th Mar 202012:24 pmRNSRedemption of 5% debenture stock
27th Mar 202011:00 amRNSHolding(s) in Company
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 202011:29 amRNSAnnual Financial Report
25th Mar 20207:00 amRNSTrading Update
19th Mar 202011:30 amRNSDirector Declaration
17th Mar 20201:15 pmRNSAdditional Listing
6th Mar 202012:00 pmRNSHolding(s) in Company
27th Feb 20207:05 amRNSDirectorate Change
27th Feb 20207:00 amRNSFinal Results
21st Feb 20204:00 pmRNSHolding(s) in Company
24th Dec 20191:10 pmRNSHolding(s) in Company
19th Dec 20192:40 pmRNSDirector/PDMR Shareholding
17th Dec 20195:10 pmRNSHolding(s) in Company
26th Nov 20196:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.